IDEA Collider: Innovation & Asymmetric Learning in Pharma

Welcome back to the IDEA Collider podcast. In this episode, host Rick Ritacco sits down with Kwame Ferreira, Founder of Synthetic Users, and Rebecca Gould, President, Strategic Consulting & Analytics Business Unit at SAI. Together, they explore how artificial intelligence and synthetic behavioral modeling are transforming pharmaceutical market research and insight generation.

For decades, market research operated under a strict constraint: you could choose two between speed, price, and quality, but never all three. 

Rebecca and Kwame discuss how synthetic user technology breaks this triangle, allowing biopharma teams to generate high-quality qualitative insights rapidly and cost-effectively. Kwame breaks down the architecture behind synthetic users—defining them as an abstraction of brain architecture that replicates human emotional responses, cognitive biases, and system 1 behaviors rather than striving for super intelligence. Rebecca shares real-world case studies in rare diseases, competitive simulation workshops, and creative concept testing where synthetic personas achieved over 90% parity with live human respondents. 

Tune in to discover how synthetic research is empowering healthcare leaders to make faster, higher-confidence decisions across the thousands of choices required to bring a medicine to market.

Keep up with the Guests

• Rebecca Gould's LinkedIn: https://www.linkedin.com/in/rebecca-gould-b30b73/
• Kwame Ferreira's LinkedIn: https://www.linkedin.com/in/kwame-ferreira-1b06a31/

Keep up with Rick Ritacco:

• LinkedIn: https://www.linkedin.com/in/rritacco/

Follow IDEA Pharma On;

• Website: https://www.ideapharma.com/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is joined by colleagues David Radwaner and Tom Brockbank to discuss what lies ahead for cancer immunotherapy. As the industry prepares for the upcoming patent expiration of Merck's dominant checkpoint inhibitor Keytruda, companies are racing to claim the next oncology backbone.

We analyze the three major strategies currently shaping the pipeline: Merck’s platform defense focusing on subcutaneous formulations and early-stage curative intent; the high-risk, high-reward displacement play of PD-1/VEGF bispecific inhibitors spearheaded by players like Akeso and Summit; and AstraZeneca’s tailored, tumor-specific approach combining immunotherapy with antibody-drug conjugates (ADCs) and targeted small molecules. The guests also dissect key clinical insights from the HARMONY-6 Phase 3 trials, the biological and tumor-localization benefits of dual-mechanism molecules over dual-drug cocktails, and the strategic importance of choosing between incremental portfolio expansion and blockbuster-seeking big bets.

Keep up with Alex Gray;

Follow IDEA Pharma On;

Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and COO of Immunic, to discuss the rapidly evolving landscape of Multiple Sclerosis (MS) treatment. For 30 years, MS therapies have primarily focused on controlling inflammation and visible relapses. Jason argues it’s time to look deeper and address the ongoing neurodegeneration driving long-term disability, known as Progression Independent of Relapse Activity (PIRA).

We explore Immunic's investigational therapy, vidofludimus calcium, and its unique dual-mechanism approach: acting as a DHODH inhibitor for anti-inflammatory benefits while also activating the Nurr1 nuclear receptor to potentially provide direct neuroprotection. Jason shares insights from the EMPHASIS and CALIBER clinical trials, discusses why the industry needs safer immunomodulators rather than just broad immunosuppressants (especially as the MS population ages), and shares a fascinating biological link between MS remission during pregnancy and Nurr1 levels. Tune in to hear what the next 10 to 15 years hold for MS patients, including the ultimate goals of halting progression entirely and achieving remyelination.

Episode Timestamps

00:00:00 - Introduction: Meet Jason Tardio, President and COO of Immunic.

00:02:01 - The Evolution of MS Treatment: Transitioning from purely anti-inflammatory approaches to addressing underlying neurodegeneration.

00:04:29 - What is PIRA?: Understanding Progression Independent of Relapse Activity and why patients still accumulate disability.

00:10:30 - The Dual-Mechanism Approach: How vidofludimus calcium combines DHODH inhibition with Nurr1 activation.

00:13:33 - The Power of Nurr1: Exploring the target's role in neuronal survival and the fascinating biological link to pregnancy in MS patients.

00:18:14 - Clinical Validation: Analyzing data from the EMPHASIS (relapsing MS) and CALIBER (progressive MS) trials.

00:27:42 - Standing Out in a Crowded Market: Why safety, tolerability, and avoiding broad immunosuppression matter, especially for aging MS patients facing immunosenescence.

00:36:08 - The Next 10 Years: Moving towards halting progression, potential remyelination, and the need to reclassify MS beyond relapsing and progressive labels.

Keep up with Jason Tardio;

LinkedIn: https://www.linkedin.com/in/jason-tardio/

Keep up with Rick Ritacco:

LinkedIn: https://www.linkedin.com/in/rritacco/

Follow IDEA Pharma On;

Website: https://www.ideapharma.com/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Welcome to a special edition of IDEA Collider’s "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic research expert, to discuss the rapidly shifting landscape of psychedelic medicine. With substantial unmet needs in treatment-resistant depression (TRD) and PTSD, the field is at a critical inflection point marked by new FDA prioritizations and breakthrough clinical data. 

Athina shares insights from her meta-analysis on psilocybin and discusses the unique methodological challenges facing the industry, such as blinding integrity and the influence of expectancy effects in clinical trials. We explore the debate over whether the "psychedelic experience" is necessary for therapeutic benefit and how biotechs are balancing regulatory-friendly trial designs with patient safety. 

Finally, Athina looks toward the future of precision psychiatry, examining the role of biomarkers and the immense logistical challenges of scaling these intensive therapies within global healthcare systems.

Don't forget to Like, Share, Subscribe, Rate, and Review!  

Keep up with Athina Metaxa; LinkedIn: 

https://www.linkedin.com/in/athina-marina-metaxa/  

Follow IDEA Pharma On; Website: 

https://www.ideapharma.com/  

Listen to more fantastic podcast episodes: 

https://ideacollider.simplecast.com/

Welcome to IDEA Collider with your host, Rick Ritacco. 

In this episode, we sit down with Sue Wood, a senior expert at IDEA Pharma with a PhD from Oxford and decades of experience translating complex scientific concepts into relevant narratives. Sue discusses the unique challenges biotechs face with early positioning, explaining why teams often struggle with the paradox of having immediate scientific certainty about a molecule but immense clinical uncertainty about its future. 

We explore how to simplify scientific messaging without "dumbing it down," and Sue shares three proven strategies: reappropriating non-pharma nomenclature, evolving familiar drug classes, and focusing on tangible clinical outcomes. Sue also highlights the importance of cross-functional alignment, noting that a team's conviction to execute a narrative often matters more than having absolute precision. 

Tune in to hear her hilarious origin story involving the Boston Globe and oat bran donuts, and learn actionable advice on what biotechs should immediately remove from their websites.

Don't forget to Like, Share, Subscribe, Rate, and Review!   

Keep up with Sue Wood; LinkedIn: https://www.linkedin.com/in/susan-wood-266631244/   

Follow IDEA Pharma On; Website: https://www.ideapharma.com/   

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic Consulting and Analytics, to discuss the intricacies of pharmaceutical portfolio strategy. 

This episode has accompanying slides that can be found on YouTube https://youtu.be/DKdy_MShWBA

They tackle the growing view that the pharmaceutical industry doesn't just have a science problem; it has an execution problem. Alex breaks down how human biases, such as confirmation bias and champion bias, can derail clinical development and lead to poor portfolio choices. They emphasize that stopping a failing project early is just as critical to an organization's overall success as advancing a good one. 

The episode explores successful decision-making frameworks from top-performing companies, analyzing how AstraZeneca's 5Rs framework reversed late-stage failures and examining structured matrices such as Roche's RAVE, Amgen's RAVE, and Pfizer's DICE. Alex also highlights Eli Lilly's highly successful Chorus unit and their use of AI to drive objective resource allocation. Tune in to hear why relying solely on standard Probability of Technical Success (PTS) models or Risk-Adjusted NPV is flawed, how operational issues drive numerous Phase 3 failures, and the incremental but powerful role machine learning will play in the next generation of drug development.

Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how PD-1 and PD-L1 therapies revolutionized cancer treatment, acting as a brake on the immune system to offer unprecedented durability and long-term survival for patients. 

They take a deep dive into the fascinating commercial and clinical race between Merck's Keytruda and BMS's Opdivo. Learn how Merck's strategic decisions—including smart statistical trial designs, targeted biomarker approaches in first-line non-small cell lung cancer, and tumor-agnostic labels like MSI-high—allowed Keytruda to secure market dominance. Finally, Alex, David, and Tom look ahead to the next ten years, discussing whether emerging players like AstraZeneca and China's Akeso / Summit will displace Keytruda, or if the future lies in combination therapies. 

Episode Timestamps: 

00:00:00 - Introduction: Meet David Radwaner, Tom Brockbank, and host Alex Gray. 

00:01:45 - The Origins of IO: The Nobel Prize-winning discovery of PD-1 and CTLA-4 checkpoints. 

00:03:55 - Why PD-1 / PD-L1 Won: The unique breadth of utility and unparalleled durability of long-term survival. 

00:06:21 - Keytruda vs. Opdivo: How Merck's strategic trial design and smart statistical work outpaced BMS's early lead. 

00:11:48 - The NSCLC Inflection Point: Why narrowing the patient population (PD-L1 - 50%) cemented Keytruda's foundation in first-line lung cancer. 

00:14:20 - Tumor-Agnostic Success: Merck's bold move into MSI-high and broad biomarker-led strategies. 

00:16:09 - Science or Luck? Analyzing Merck's aggressive and risky clinical development strategy. 

00:18:00 - The Next 10 Years: Will anyone displace Keytruda? Assessing the future strategies of Merck, BMS, AstraZeneca, and Akeso/Summit 

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Alex Gray; 

LinkedIn: https://www.linkedin.com/in/alexander-gray-934a653/ 

Keep up with David Radwaner; 

LinkedIn: https://www.linkedin.com/in/david-radwaner-1b496343/ 

Keep up with Tom Brockbank; 

LinkedIn: https://www.linkedin.com/in/tom-brockbank-159bb4116/   

Follow IDEA Pharma On; Website: https://www.ideapharma.com/   

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next frontier in cancer treatment—particularly for solid tumors. 

While CAR-T therapy has transformed outcomes in hematologic cancers, its success has been limited in solid tumors due to a lack of suitable targets. Reagan explains how T-cell receptor (TCR) therapies overcome this challenge by targeting HLA-presented peptide antigens, enabling access to tumor-specific biology that CAR-T cannot reach. 

Anocca is building a fully integrated platform that combines: Target mapping of HLA-peptide complexes Rapid generation of optimized T-cell receptors from healthy donors Non-viral gene editing for faster, lower-cost manufacturing End-to-end control from discovery through clinical development.

The conversation also highlights Anocca’s first clinical program targeting mutant KRAS in pancreatic ductal adenocarcinoma, using an umbrella trial design, early intervention strategies, and biomarkers such as circulating tumor DNA (ctDNA). Reagan shares insights on regulatory pathways for individualized therapies, the commercial challenges of patient segmentation, and how software, data, and machine learning are becoming essential to scaling cell therapy platforms. 

This episode is a must-listen for anyone interested in cell therapy innovation, cancer immunotherapy, and the future of precision medicine. 

Episode Timestamps 

00:00 – Introduction to TCR-T and solid tumor challenges 

00:48 – Meet Reagan Jarvis and Anocca 

02:05 – From New Zealand to Sweden: founder journey 

03:08 – Frustration that sparked the platform 

04:33 – Why CAR-T struggles in solid tumors 

07:24 – The advantage of vertical integration in biotech 

09:23 – First non-viral clinical trial challenges 

10:56 – Umbrella trials in pancreatic cancer (KRAS focus) 

14:13 – Biomarkers and building a target library 

17:08 – Software, data, and machine learning in TCR discovery 

18:08 – Regulatory pathways for individualized therapies 

19:19 – Commercial landscape and target bottlenecks 

22:29 – Expanding beyond oncology and partnerships 

23:51 – Building a biotech company in Sweden 

27:12 – Misconceptions about T-cell biology 

30:04 – Milestones and 5-year vision 

32:32 – Advice for scientific founders 

34:17 – Closing thoughts 

Don't forget to Like, Share, Subscribe, Rate, and Review!   

Keep up with Reagan Jarvis; 

LinkedIn: https://www.linkedin.com/in/reagan-jarvis-063984142/ 

Website: https://www.anocca.com/  

Follow IDEA Pharma 

Website: https://www.ideapharma.com/ 

LinkedIn: https://www.linkedin.com/company/idea-pharma/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech’s most complex transformations. 

After the rapid rise and decline of COVID-19 revenues tied to sotrovimab, Marianne stepped into Vir Bio in 2023 and led a bold strategic reset—refocusing the company on immuno-oncology, infectious disease, and platform-driven innovation. 

The conversation dives into Vir Bio’s next chapter, including its masked T-cell engager (TCE) pipeline and the PRO-XTEN® masking platform, which is designed to overcome the safety challenges of TCEs in the treatment of solid tumors by shielding therapies until they reach the tumor microenvironment. 

They also discuss Vir Bio’s advancing hepatitis delta program, currently in registrational Phase 3 trials, and the company’s growing pipeline leveraging the synergy of its AI-driven discovery, protein engineering capabilities, and universal PRO-XTEN® masking technology. 

Marianne shares what it takes to lead through a biotech downturn—from restructuring and capital discipline to rebuilding culture, integrating new teams, and positioning for long-term growth. 

This episode is a deep dive into biotech turnaround strategy, next-generation cancer therapies, and leadership in times of uncertainty. Episode 

Timestamps 

00:00 – Introduction and Vir’s transformation story 

00:40 – Marianne De Backer’s 30+ year pharma journey 

02:42 – Vir’s origins and post-COVID strategic pivot 

04:42 – Taking over as CEO during a crisis 

06:33 – Lessons from the biotech downturn (“biotech winter”) 

08:56 – Astellas partnership and T-cell engager strategy 

09:52 – ProXtend platform: masked T-cell engagers explained 

13:24 – Clinical data, safety, and tumor targeting 

15:32 – Integrating new teams and scientific expertise 

17:38 – Expanding the pipeline (HER2, EGFR, oncology) 

19:50 – Hepatitis delta program and commercialization plans 

22:11 – Funding strategy and biotech market outlook 

25:37 – FDA interactions and regulatory perspective 

28:13 – AI in drug discovery and clinical trials (Daisy platform) 

31:34 – Culture: grit, ingenuity, collaboration, authenticity 

34:21 – Personal reflections and leadership mindset 

35:46 – Closing thoughts 

Don't forget to Like, Share, Subscribe, Rate, and Review!   

Keep up with Marianne De Backer; 

LinkedIn: https://www.linkedin.com/in/marianne-d-de-backer-msc-phd-mba-73403411/ 

Website: https://www.vir.bio/   

Follow IDEA Pharma On; 

Website: https://www.ideapharma.com/ 

LinkedIn: https://www.linkedin.com/company/idea-pharma  

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of the IDEA Collider, host Mike Rea sits down with Warner Biddle, CEO of Kyverna Therapeutics, to explore how CAR-T cell therapy is expanding beyond oncology into autoimmune disease—and what it takes to scale one of the most complex innovations in modern medicine. 

Warner shares insights from his career across large pharma and biotech, breaking down why cell therapy requires a fundamentally different operating model—one that tightly integrates manufacturing, clinical execution, and commercialization. The conversation dives into how Kyverna is advancing CAR-T therapies for neuroimmunology indications, including stiff person syndrome (SPS), myasthenia gravis, multiple sclerosis, and rheumatoid arthritis, while preparing its first Biologics License Application (BLA).

They also unpack the broader cell therapy ecosystem, from improving hospital capacity and enabling outpatient treatment to evolving FDA regulatory pathways, CMC guidance, and REMS simplification—all critical to making CAR-T more accessible and scalable. Warner emphasizes that success in this space depends on trust-driven leadership, speed, and a willingness to embrace risk, while also highlighting the growing global competition—particularly from China—as a catalyst for faster innovation. 

Episode Timestamps 

00:00 – Introduction to CAR-T and the future of autoimmune disease treatment 

00:18 – Meet Warner Biddle and his journey across pharma and biotech 

01:26 – Building a culture of innovation, trust, and speed 

02:45 – Why cell therapy is fundamentally different from traditional drugs 

03:57 – Ecosystem shifts: access, infrastructure, and outpatient care 

06:03 – FDA tailwinds: CMC guidance, REMS changes, and regulatory momentum 

07:24 – Kyverna’s strategy and rapid progress in stiff person syndrome (SPS) 

09:04 – Manufacturing challenges and scaling CAR-T production 

10:25 – Commercializing one-time therapies in a traditional pharma model 

11:47 – Clinical impact of CAR-T in autoimmune diseases 

13:32 – Investor momentum and biotech market dynamics 

14:13 – Leadership principles: trust, urgency, and decision-making 

18:33 – Scaling biotech while maintaining agility 

20:56 – Expanding access: bringing CAR-T to community settings 

23:24 – China’s accelerating innovation in cell therapy 

26:18 – 2026 milestones and Kyverna’s pipeline outlook 

29:43 – Closing thoughts 

Don't forget to Like, Share, Subscribe, Rate, and Review!   

Keep up with Warner Biddle; 

LinkedIn: https://www.linkedin.com/in/warnerbiddle/ 

Website: https://kyvernatx.com/   

Follow IDEA Pharma On; 

Website: https://www.ideapharma.com/ & https://www.sai-med.com/

LinkedIn: https://www.linkedin.com/company/idea-pharma 

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/